Casein small peptides and their uses in regulating pituitary secretion

By employing a two-step enzymatic hydrolysis and calcium-selective phase inversion method to remove impurities, enriched casein small molecule peptides were prepared, overcoming the shortcomings of existing technologies in the regulation of pituitary hormone secretion by casein hydrolysates. This method enables the preparation of high-purity active peptides and the improvement of pituitary secretion disorders.

CN123106868APending Publication Date: 2026-11-17DAYA QIANYUAN (HANGZHOU) TECH CO LTD +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611305839.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-08-26
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing casein hydrolysates lack specific active sequences in regulating pituitary hormone secretion, and their batch-to-batch activity varies greatly, making it difficult to effectively regulate pituitary secretion disorders.

Method used

A two-step enzymatic hydrolysis and calcium-selective phase inversion method was used to prepare casein-enriched small peptides, which were then purified by C18 reversed-phase chromatography to obtain active peptides with specific amino acid sequences for regulating pituitary hormone secretion.

Benefits of technology

It achieves high-purity enrichment of bioactive peptides, significantly improves the background abundance of target bioactive peptides, and can regulate pituitary hormone secretion and improve HPA axis disorder.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123106868A_ABST
    Figure CN123106868A_ABST
Patent Text Reader

Abstract

Casein small molecule peptides and their use in regulating pituitary secretion belong to the fields of milk-derived bioactive polypeptides, functional foods, and endocrine regulation biomedical technology. They are used to treat pituitary hormone secretion disorders. The amino acid sequence of milk-derived casein peptides is Ile-Thr-Pro-Thr-Leu-Asn-Arg.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the fields of milk-derived bioactive peptides, functional foods, and endocrine regulation biomedicine. Specifically, it relates to a small molecule peptide derived from bovine milk casein that can regulate pituitary hormone secretion, and more particularly to the preparation method of this casein small molecule peptide, as well as the application of this peptide in the preparation of products related to regulating the pituitary-hypothalamic endocrine axis and improving pituitary secretion disorders. Background Technology

[0002] The pituitary gland is an important endocrine center in the human body, regulated by the hypothalamus. It synthesizes and secretes various key hormones, including adrenocorticotropic hormone (ACTH), thyroid-stimulating hormone (TSH), and growth hormone (GH). Prolonged stress, irregular sleep patterns, and subclinical stress can easily lead to an imbalance in pituitary secretion rhythms, manifesting as hormonal rhythm disorders, HPA axis hyperactivity, fatigue, and other subclinical endocrine imbalances. Food-derived small-molecule bioactive peptides can be absorbed through the intestines and indirectly regulate the hypothalamus-pituitary pathway via the endocrine-gut-brain axis, possessing the potential to mildly regulate pituitary secretion.

[0003] Bovine milk casein is an important raw material for the preparation of food-derived bioactive peptides. Existing casein hydrolysates are mostly concentrated in anti-anxiety, sleep improvement, anti-oxidation, and immune regulation; very few are specifically developed for the targeted preparation of peptides that regulate pituitary hormone secretion; most products are mixed hydrolysates without clear characteristic active sequences, and the activity of each batch varies greatly.

[0004] Calcium ions can chelate with phosphorylated serine, Glu, and Asp acidic residues on polypeptide chains, and there are significant differences in the aqueous solubility of different peptide-calcium complexes. This physicochemical phenomenon is well known, but how to use this solubility difference to precipitate and remove impurity peptides, while simultaneously matching specific time-restricted enzymatic hydrolysis to obtain pituitary regulatory active peptides, has not been publicly reported. Summary of the Invention

[0005] To address the issue of whether bioactive peptides can be used to regulate pituitary hormone secretion, in a first aspect, the bioactive peptides described in some embodiments of this application have the amino acid sequence shown in SEQ ID NO:1.

[0006] In a second aspect, the method for preparing milk-derived casein peptides according to some embodiments of this application includes:

[0007] Trypsin was added to the aqueous solution of milk-derived casein for the first enzymatic hydrolysis, and the enzyme was then inactivated.

[0008] Add aminopeptidase for the second enzymatic hydrolysis, inactivate the enzyme, and then perform the first centrifugation to precipitate.

[0009] Free calcium ions are added to form chelates with the heteropeptides, followed by a second centrifugation precipitation. The milk-derived casein peptides are obtained from the supernatant.

[0010] According to the method for preparing milk-derived casein peptides described in some embodiments of this application, the method further includes purifying an aqueous solution prepared from the peptide powder of the milk-derived casein peptides by passing it through a C18 reversed-phase chromatography column, wherein the concentration of the aqueous solution prepared from the peptide powder is 9~11 mg / mL, and 0.5~1.0 mL is taken for loading.

[0011] The C18 reversed-phase chromatographic column has a specification of 250mm × 20mm and a packing particle size of 10μm;

[0012] Mobile phase A is 0.1% (v / v) trifluoroacetic acid aqueous solution, mobile phase B is acetonitrile, the flow rate is 18~20 mL / min, and the column temperature is 24~26℃;

[0013] Elution was performed using the following gradient elution procedure:

[0014] From 0 to 5 minutes, the volume percentage of mobile phase B was 12%.

[0015] Within 5–25 minutes, the volume percentage of mobile phase B increased linearly from 12% to 35%.

[0016] 25~30 min, the volume percentage of mobile phase B is 35%;

[0017] After 30-35 minutes, the volume percentage of mobile phase B is 12%.

[0018] The elution peak with a retention time of 8.2-9.0 min was collected at a detection wavelength of 220 nm to obtain the casein peptide.

[0019] According to the method for preparing milk-derived casein peptides described in some embodiments of this application, trypsin is added to an aqueous solution of milk-derived casein for a first enzymatic hydrolysis and enzyme inactivation. The amount of trypsin used is 1% to 2% based on the mass of the casein substrate, and the result is a first enzymatic hydrolysate. The temperature of the first enzymatic hydrolysis is 50 to 55°C, the pH is 7.8 to 8.5, and the time is 2 to 3 hours.

[0020] According to the method for preparing milk-derived casein peptides described in some embodiments of this application, an aminopeptidase is added to a first enzymatic hydrolysate and the enzyme is inactivated. The amount of aminopeptidase is 0.25-0.5% based on the mass of the casein substrate, and the resulting solution is a second enzymatic hydrolysate. The second enzymatic hydrolysis is performed at a temperature of 45-50°C, a pH of 7.8-8.5, and a time of 30-40 minutes.

[0021] According to the method for preparing milk-derived casein peptides described in some embodiments of this application, the second enzymatic hydrolysate is subjected to a first centrifugal precipitation, the first supernatant is collected, free calcium ions are added to the first supernatant under stirring conditions at pH 6.5~7.0, a second centrifugal precipitation is performed, the second supernatant is collected, and the casein peptides are obtained from the second supernatant.

[0022] According to the method for preparing milk-derived casein peptides described in some embodiments of this application, the free calcium ions are derived from calcium chloride.

[0023] According to the method for preparing milk-derived casein peptides described in some embodiments of this application, the milk-derived casein is derived from bovine milk casein.

[0024] According to the method for preparing milk-derived casein peptides described in some embodiments of this application, the amount of calcium chloride used is such that the final concentration of calcium ions in the first supernatant reaches 12-16 mmol / L.

[0025] According to the method for preparing milk-derived casein peptides described in some embodiments of this application, the preparation of bovine milk casein aqueous solution includes thoroughly stirring and dissolving the bovine milk casein aqueous solution under conditions of pH 7.8-8.2 and temperature 45-50°C to prepare a bovine milk casein aqueous solution with a mass fraction of 6-8%.

[0026] According to the method for preparing milk-derived casein peptides described in some embodiments of this application, the enzyme inactivation conditions for the first enzymatic hydrolysis and / or the second enzymatic hydrolysis are incubation at 80~85℃ for 10~15 min.

[0027] According to the method for preparing milk-derived casein peptides described in some embodiments of this application, the first centrifugal precipitation includes centrifugation for 15 min at 8000 r / min and 4°C.

[0028] According to the method for preparing milk-derived casein peptides described in some embodiments of this application, the second centrifugal precipitation includes standing at room temperature for 20-30 minutes and centrifuging at 8000 r / min for 15 minutes.

[0029] On a third-party level, the application of the active peptides described in some embodiments of this application in the preparation of medicaments, functional foods, or health products for treating pituitary hormone secretion disorders.

[0030] Beneficial effects:

[0031] In the first aspect, the present invention proposes a small casein peptide derived from the αs2-casein hydrolysis fragment, the amino acid sequence of which includes: Ile-Thr-Pro-Thr-Leu-Asn-Arg (ITPTLNR, SEQ ID NO: 1), with a molecular weight of 813.95 Da. This active peptide can act on pituitary gland cells to regulate the basal secretion levels of ACTH and TSH.

[0032] In a second aspect, the active peptide preparation method of the present invention addresses the shortcomings of existing indiscriminate enzymatic hydrolysis of casein peptides, which leads to excessive degradation of active precursors and low background abundance of target active peptides. This method includes steps such as restrictive enzymatic hydrolysis and calcium-selective phase inversion for impurity removal, yielding small casein peptides enriched with the target active peptides. The resulting products can regulate pituitary hormone secretion and improve HPA axis disorder.

[0033] Existing water-ethanol mixtures are used to prepare casein phosphopeptides (CPP). The target peptide precipitates, and the precipitate is collected to obtain the casein phosphopeptide. This invention, however, prepares active peptides in an all-aqueous phase without adding ethanol. Calcium ions are used to induce a phase inversion and precipitation of a large number of inactive peptides, while the target active peptide remains in the supernatant. The supernatant is collected as the enriched component. The two methods involve completely opposite phase separations and have entirely different applications. In CPP preparation, the separation is used to promote calcium absorption, while in this invention, the separation is used to obtain the product for pituitary endocrine regulation.

[0034] This invention uses two steps, including enzymatic hydrolysis and calcium-selective phase inversion for impurity removal, to obtain a casein small molecule peptide product enriched with the active peptide, wherein the target active peptide of SEQ ID NO:1 accounts for 11-14% by mass. Furthermore, this invention provides a step for further purification using reverse chromatography, achieving an HPLC purity of approximately 91.6%. Attached Figure Description

[0035] Figure 1 Chromatogram of milk-derived casein peptides

[0036] Figure 2 Bar chart of hypothalamic CRH mRNA and pituitary POMC mRNA. Detailed Implementation

[0037] This invention prepares milk-derived casein peptides, and the preparation steps include:

[0038] S1. Casein raw material is dissolved;

[0039] S2. First-stage restriction enzyme digestion followed by immediate heat inactivation of the restriction enzyme;

[0040] S3. Second stage: short-term modification with low dose of exopeptidase, followed by enzyme inactivation;

[0041] S4. Centrifugation removes denatured macromolecular precipitates;

[0042] S5. Calcium-selective phase inversion is used to remove impurities (discard the precipitate and retain the supernatant) to obtain casein-enriched peptides containing the target active peptides.

[0043] Specifically:

[0044] Step S1. Dissolve casein raw materials, including food-grade bovine milk casein, to prepare a protein aqueous solution with a mass fraction of 6-8%; adjust the pH to 7.8-8.2, stir thoroughly at 45-50℃ to remove insoluble impurities, such as water-insoluble protein.

[0045] Step S2. Endonuclease restriction hydrolysis, including the addition of trypsin for hydrolysis, with the amount of enzyme added being 1-2% of the casein substrate (i.e., the casein raw material in step S1) by mass; temperature 50-55℃, pH maintained at 7.8-8.5, hydrolysis time 2-3h; this step relies on endonuclease to cleave the long chain of casein, releasing the active peptide precursor fragment containing SEQ ID NO:1. After hydrolysis, the temperature is rapidly raised to 80-85℃ and held for 10-15min to immediately inactivate all endonuclease.

[0046] Step S3. Short-term modification with exopeptidase, including cooling the system to 45-50°C; adding aminopeptidase at an amount of 0.25-0.5% of the casein substrate mass, maintaining pH at 7.8-8.5, and hydrolyzing for 30-40 minutes; this step only moderately removes free amino acids from both ends of the peptide and trims the peptide ends. After hydrolysis, immediately raise the temperature to 80-85°C and hold for 10-15 minutes to completely inactivate the enzyme. This invention found that neither adding two enzymes simultaneously nor changing the order of addition can achieve an enrichment effect.

[0047] Step S4. Centrifuge to remove denatured macromolecular precipitates, including cooling the feed solution, centrifuging at 8000 r / min and 4℃ for 15 min to remove heat-denatured macromolecular protein precipitates, and collecting the supernatant enzymatic hydrolysate.

[0048] Step S5. Calcium-selective phase inversion for impurity removal includes adjusting the pH of the enzymatic hydrolysis supernatant after centrifugation to 6.5-7.0, slowly adding calcium chloride under stirring to achieve a final calcium ion concentration of 12-16 mmol / L, and allowing it to stand at room temperature for 20-30 min. This allows a large number of hydrophobic and hyperphosphorylated peptides to form chelates with calcium ions, resulting in a solid-liquid phase inversion and precipitation. The precipitate is removed by centrifugation, and the supernatant is collected to obtain the casein small molecule peptide solution of this invention. The solution is then concentrated and dried to obtain casein small molecule peptide powder, wherein the target active peptide SEQ ID NO:1 accounts for 11-14%.

[0049] This invention relates to casein small molecule peptides for the preparation of oral medications and functional dietary supplements that regulate pituitary secretion and improve clinical secretory disorders of the hypothalamus-pituitary axis; dosage forms include capsules, tablets, oral liquids, and solid beverages. This invention is not simply a matter of sequentially adding two proteases; the key lies in the immediate thermal inactivation of the endopeptidase after the endopeptidase reaction, followed by short-term modification with an exopeptidase, and then further enzyme inactivation. Compared to other complex random enzymatic hydrolysis processes, simultaneous addition of the aforementioned endopeptidase and exopeptidase, and reverse enzymatic hydrolysis, the background abundance of the target peptide in the product is significantly increased. This invention uses an all-aqueous, ethanol-free system, where calcium ions promote the precipitation and removal of impurity peptides, while the target active peptide is retained in the supernatant, resulting in enriched peptides with a target active peptide content of 11-14%. The process involves fewer units, reducing investment in industrial equipment and facilitating scale-up.

[0050] The enriched product of this invention was further prepared by C18 chromatography to obtain a high-purity target active peptide. This peptide was used in vitro with primary rat pituitary cells and in vivo in a chronic stress rat model, demonstrating that it can regulate ACTH hormone secretion and improve HPA axis disorder. The chromatographic column used was a C18 column (250 mm × 20 mm, 10 μm); mobile phase A was 0.1% trifluoroacetic acid aqueous solution, and mobile phase B was acetonitrile; the flow rate was 18–20 mL / min, and the column temperature was 25 °C; the gradient elution program was: 0–5 min 12% B, 5–25 min 12% → 35% B linear gradient, 25–30 min 35% B, 30–35 min 12% B equilibration; the detection wavelength was 220 nm, and the elution peak with a retention time of 8.2–9.0 min was collected to obtain the casein peptide. The peptide powder was prepared from the supernatant.

[0051] Example 1: Preparation of casein small molecule enriched peptides

[0052] S1.500g of food-grade bovine casein was prepared into an 8% (w / w) aqueous solution, pH 8.0, and stirred at 50℃ until fully dissolved.

[0053] S2. Endopeptidation restriction digestion: Add 5.5g of trypsin, digest at 53℃ and pH 7.9 for 2.5h; incubate at 85℃ for 10min to inactivate all trypsin.

[0054] S3. Short-term modification with low-dose exopeptidase: Cool the solution to 45°C and maintain pH at 7.9; add 1.25g of aminopeptidase and hydrolyze for 40min; incubate at 85°C for 10min to completely inactivate the enzyme.

[0055] S4. Centrifuge to remove denatured precipitate: Centrifuge at 8000 r / min, 4℃ for 15 min, discard the precipitate, and collect the enzymatic supernatant.

[0056] S5. Calcium-selective phase inversion for impurity removal: Adjust pH to 6.9; slowly add calcium chloride with stirring until the final calcium ion concentration is 14 mmol / L; let stand at room temperature for 30 min; centrifuge at 8000 r / min for 15 min, discard the precipitate, and collect the supernatant to obtain the peptide solution. Concentrate the peptide solution under reduced pressure and freeze-dry under vacuum to obtain 51.2 g of casein small molecule enriched peptide powder, with the target active peptide (milk-derived casein peptide SEQ ID NO: 1) accounting for 12.3%.

[0057] Example 2: Laboratory preparation of high-purity milk-derived casein peptides

[0058] The casein small molecule enriched peptide powder obtained in Example 1 was diluted with deionized water to 10 mg / mL and purified by C18 column chromatography. The column size was 250 mm × 20 mm, and the packing particle size was 10 μm. Mobile phase A was 0.1% (v / v) trifluoroacetic acid aqueous solution, and mobile phase B was acetonitrile. The flow rate was 18-20 mL / min, and the column temperature was 25 °C. The gradient elution program was: 0-5 min 12% B, 5-25 min 12% → 35% B linear gradient, 25-30 min 35% B, 30-35 min 12% B equilibration. The detection wavelength was 220 nm, and the elution peak with a retention time of 8.2-9.0 min was collected to obtain a high-purity sample of milk-derived casein peptide (SEQ ID NO: 1) with an HPLC purity of 91.6%. Figure 1 This is a chromatogram of casein peptides from milk.

[0059] Experimental Example

[0060] Experiment Example 1: In Vitro Secretion Regulation Experiment Using Primary Rats' Pituitary Cells

[0061] Cells and reagents: SD rat primary pituitary cells; DMEM / F12 complete culture medium; CRH (corticotropic hormone-releasing hormone, Sigma); CCK-8 cytotoxicity assay kit; ACTH and TSHELISA assay kits.

[0062] Test substance: High-purity milk-derived casein peptides (Example 2);

[0063] The experiment was divided into groups, with 6 replicates per group, including...

[0064] Blank control group: primary pituitary cells, cultured with an equal volume of solvent;

[0065] Model control group: 100nMCRH combined stimulation for 2 hours to create a state of high pituitary hormone secretion;

[0066] Low-dose peptide group: model stimulation + 50 μg / mL Example 2 High-purity milk-derived casein peptide;

[0067] Medium-dose peptide group: Model stimulation + 100 μg / mL Example 2 High-purity milk-derived casein peptide;

[0068] High-dose peptide group: Model stimulation + 200 μg / mL Example 2 High-purity milk-derived casein peptide;

[0069] Medium-dose non-stimulating group of peptides: 100 μg / mL Example 2 High-purity milk-derived casein peptides;

[0070] Procedure: Rat pituitary tissue was aseptically isolated, and primary pituitary cells were prepared by enzymatic digestion; cells were cultured at a concentration of 1.5 × 10⁻⁶. 5 Cells were seeded per well in 24-well plates; incubated at 37°C and 5% CO2 for 24 hours to allow cell adhesion; the model group and each drug-treated group were replaced with serum-free medium containing 100 nMCH, and the blank control group was replaced with serum-free medium containing an equal volume of solvent, pre-stimulated at 37°C for 2 hours; each drug-treated group was replaced with CRH-stimulated medium containing the corresponding concentration of the test peptide, except that the medium-dose peptide without stimulation group was replaced with CRH-free medium containing the corresponding concentration of the test peptide, and the blank control group and model control group were replaced with the corresponding medium containing an equal volume of solvent, and incubated for another 24 hours; the cell culture supernatant was collected, and the ACTH hormone concentration in the supernatant was determined using an ELISA kit; another batch of cells was seeded into 96-well plates according to the same grouping (…). (cells / well), after incubation, add 10 μL CCK-8 solution to each well, incubate at 37℃ for 2 h, measure absorbance at 450 nm using a microplate reader, and calculate relative cell viability.

[0071] Statistical methods: Data are expressed as Mean ± SD; SPSS one-way ANOVA was used. P < 0.05 was considered statistically significant, and P < 0.01 was considered extremely significant.

[0072] Table 1. ACTH secretion level and relative cell viability in primary pituitary cells supernatant.

[0073]

[0074] Note: ## Compared with the blank control group, P<0.01; ** Compared with the model control group, P<0.01.

[0075] Results Analysis: Compared with the model control group, milk-derived casein peptides dose-dependently downregulated excessive ACTH secretion by primary pituitary cells (P < 0.01). Furthermore, CCK-8 assays showed that the relative cell viability in all treatment groups was >95%, with no significant difference compared to the control group, ruling out the possibility that the decreased hormone secretion was caused by cytotoxicity. Simultaneously, the medium-dose, unstimulated group showed no significant difference compared to the blank group, indicating that milk-derived casein peptides only counteract stress-induced hypersecretion and do not disrupt normal physiological basal secretion. These results confirm that the milk-derived casein peptides of this invention can directly act on pituitary cells, inhibiting excessive ACTH secretion induced by secretagogue hormones, rather than non-specifically inhibiting basal secretion or killing cells.

[0076] Experiment Example 2: Effect of HPA-Pituitary Axis Regulation in Chronic Stress Rats

[0077] Experimental Objective: To evaluate the regulatory effects of milk-derived casein peptides on pituitary hormones and serum corticosterone using a chronic unpredictable mild stress (CUMS) rat model that induces hypothalamic-pituitary-adrenal axis dysfunction and abnormally elevated pituitary ACTH secretion, simulating subclinical pituitary secretory disorders.

[0078] Experimental animals: 60 male SPF-grade SD rats, weighing 200±15g; acclimatized for 7 days; randomly divided into 5 groups of 12 rats each: normal control group, model control group, low-dose polypeptide group, and high-dose polypeptide group.

[0079] Modeling and Drug Administration: Except for the normal control group, all other groups were modeled using chronic unpredictable mild stress (CUMS). A sucrose preference test was performed on day 27 after modeling. After 24 hours of fasting and deprivation of water, rats were simultaneously given two bottles of liquid (1% sucrose solution and pure water). The consumption of both bottles of liquid within 1 hour was measured, and the sucrose preference rate was calculated as follows: Sucrose preference rate (%) = (sucrose solution consumption / (sucrose solution consumption + pure water consumption)) × 100%. For 28 consecutive days, an HPA axis hyperactivity and pituitary ACTH hypersecretion model was established. The drug was administered daily by gavage during modeling. The normal and model control groups were given an equal volume of physiological saline. The low dose of the peptide was 10 mg / kg·d; the high dose of the peptide was 26 mg / kg·d; the test substance administered was the milk-derived casein peptide from Example 2.

[0080] Detection indicators: After 28 days of drug administration and model establishment, blood was collected from the abdominal aorta of anesthetized rats; serum ACTH (pituitary secretion) and serum corticosterone CORT were detected by ELISA. After blood collection, hypothalamus and pituitary tissues were quickly separated, and the relative expression levels of hypothalamic CRH mRNA and pituitary POMC mRNA were detected by qRT-PCR (using GAPDH as an internal reference, calculated by the 2^-ΔΔCt method).

[0081] Table 2 Serum endocrine markers in CUMS chronically stressed rats

[0082]

[0083] Note: ## Compared with the normal control group, P<0.01; * Compared with the model control group, P<0.05; ** Compared with the model control group, P<0.01.

[0084] Results analysis: Compared with the normal control group, the model control group showed a significant decrease in sucrose preference rate and a significant increase in serum ACTH and corticosterone (P<0.01), indicating that the CUMS-induced pituitary-HPA axis hyperactivity model was successfully constructed.

[0085] From Table 2 and Figure 2It was found that, compared with the model control group, the high-dose group of the present invention's peptides significantly improved depressive-like behavior (rebound in sucrose preference rate) in CUMS rats, dose-dependently reduced serum ACTH and corticosterone, and significantly downregulated the overexpression of hypothalamic CRH mRNA and pituitary POMC mRNA. These results, from behavioral, peripheral endocrine, and central gene expression perspectives, confirm that the casein peptides of the present invention can effectively improve chronic stress-induced pituitary secretory disorders and regulate the function of the hypothalamus-pituitary endocrine axis in vivo.

[0086] Experiment Example 3: Comparative Verification Experiment on the Abundance of Target Peptides in Products from Different Enzymatic Hydrolysis Processes

[0087] Comparative Example A (Traditional Compound Enzymatic Hydrolysis Control Group): The same casein raw material was prepared into the same 8% protein solution; trypsin (1.1%) + aminopeptidase (0.25%) were added to the same system at the same time; enzymatic hydrolysis was carried out at 53℃ for 3 hours; enzyme was directly inactivated at 85℃; all subsequent centrifugation and calcium phase conversion process parameters were completely consistent with those of Example 1.

[0088] Comparative Example B (Reverse Enzymatic Hydrolysis Control Group): The raw material preparation was the same as in Example 1; 1.25g of aminopeptidase was added first, and the enzyme was hydrolyzed at 45℃ for 40min, and then inactivated at 85℃; then the temperature was lowered to 53℃, 5.5g of trypsin was added, and the enzyme was hydrolyzed for 2.5h, and then inactivated at 82℃; all subsequent processes were completely consistent with Example 1.

[0089] Detection indicators: the yield of SEQ ID NO:1 milk-derived casein peptide in casein small molecule peptide powder, yield (%) = (pure amount of target peptide / amount of original casein feed) * 100%; the enriched peptides of each group were uniformly administered at 100 μg / mL to determine the ACTH secretion level of pituitary cells.

[0090] Table 3. Crude product indicators and cell viability after purification from different enzymatic hydrolysis processes.

[0091]

[0092] Results Analysis: Traditional simultaneous addition of endopeptidase (A) resulted in continuous degradation of the target peptide, leading to the lowest crude peptide abundance. Reverse enzymatic digestion (B), involving exopeptidase followed by endopeptidase, almost failed to yield high-abundance target peptides. Only the complete process of this invention, which involves immediate heat inactivation of the endopeptidase after the first-stage endopeptidase process followed by short-term exopeptidase modification, can yield high-background target peptides. Furthermore, combined with all-aqueous calcium-phase conversion for impurity removal, significant enrichment is achieved, resulting in optimal in vitro pituitary regulatory activity.

[0093] Finally, it should be noted that the above examples are merely a few specific embodiments of the present invention. All derivatives that can be directly derived or conceived by those skilled in the art from the content disclosed in this invention should be considered within the scope of protection of this invention.

Claims

1. An active peptide, characterized in that, Its amino acid sequence is shown in SEQ ID NO:

1.

2. A method for preparing milk-derived casein peptides, characterized in that, include: Trypsin was added to the aqueous solution of milk-derived casein for the first enzymatic hydrolysis, and the enzyme was then inactivated. Add aminopeptidase for the second enzymatic hydrolysis, inactivate the enzyme, and then perform the first centrifugation to precipitate. Free calcium ions are added to form chelates with the heteropeptides, followed by a second centrifugation precipitation. The milk-derived casein peptides are obtained from the supernatant.

3. The method according to claim 2, characterized in that, It also includes purifying an aqueous solution prepared from the peptide powder of the milk-derived casein peptide by passing it through a C18 reversed-phase chromatography column, wherein the concentration of the aqueous solution prepared from the peptide powder is 9~11 mg / mL, and 0.5~1.0 mL is taken for loading. The C18 reversed-phase chromatographic column has a specification of 250mm × 20mm and a packing particle size of 10μm; Mobile phase A is 0.1% (v / v) trifluoroacetic acid aqueous solution, mobile phase B is acetonitrile, the flow rate is 18~20 mL / min, and the column temperature is 24~26℃; Elution was performed using the following gradient elution procedure: From 0 to 5 minutes, the volume percentage of mobile phase B was 12%. Within 5–25 minutes, the volume percentage of mobile phase B increased linearly from 12% to 35%. 25~30 min, the volume percentage of mobile phase B is 35%; After 30-35 minutes, the volume percentage of mobile phase B is 12%. The elution peak with a retention time of 8.2 to 9.0 min was collected at a detection wavelength of 220 nm to obtain the casein peptide.

4. The method according to claim 2, characterized in that, in, Trypsin was added to an aqueous solution of milk-derived casein for the first enzymatic hydrolysis and enzyme inactivation. The amount of trypsin used was 1% to 2% based on the mass of the casein substrate. The resulting solution was the first enzymatic hydrolysate. The temperature of the first enzymatic hydrolysis was 50 to 55°C, the pH was 7.8 to 8.5, and the time was 2 to 3 hours.

5. The method according to claim 2, characterized in that, in, Add aminopeptidase to the first enzymatic hydrolysate and inactivate the enzyme. The amount of aminopeptidase is 0.25-0.5% based on the mass of casein substrate. The resulting enzymatic hydrolysate is the second enzymatic hydrolysate. The second enzymatic hydrolysate is carried out at a temperature of 45-50℃, a pH of 7.8-8.5, and a time of 30-40 min.

6. The method according to claim 2, characterized in that, in, The second enzymatic hydrolysate is subjected to a first centrifugation precipitation, and the first supernatant is collected. Free calcium ions are added to the first supernatant under stirring at a pH of 6.5-7.0, and a second centrifugation precipitation is performed. The second supernatant is collected, and the casein peptide is obtained from the second supernatant.

7. The method according to claim 2, characterized in that, in, Free calcium ions are derived from calcium chloride; preferably, the milk casein is derived from bovine milk casein.

8. The method according to claim 2, characterized in that, in, The amount of calcium chloride used is to achieve a final calcium ion concentration of 12-16 mmol / L in the first supernatant.

9. The method according to claim 2, characterized in that, The preparation of bovine casein aqueous solution involves thoroughly stirring and dissolving bovine casein aqueous solution at a pH of 7.8-8.2 and a temperature of 45-50℃ to prepare a bovine casein aqueous solution with a mass fraction of 6-8%. Preferably, the enzyme inactivation conditions for the first and / or second enzymatic hydrolysis are incubation at 80-85°C for 10-15 minutes; Preferably, the first centrifugal precipitation includes centrifugation for 15 min at 8000 r / min and 4°C; Preferably, the second centrifugal precipitation includes standing at room temperature for 20-30 minutes and centrifuging at 8000 r / min for 15 minutes.

10. The use of the active peptide of claim 1 in the preparation of a medicine, functional food, or health product for treating pituitary hormone secretion disorders.